Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Arcturus Therapeutics Holdings Inc's Business Segments
Arcturus Therapeutics Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Grant
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Grant0%
- Gates Foundation Grant50.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 4 | - |
| Gates Foundation Grant | $ 1 | 50.4% |
Revenue by Product & Service Category - FY
- Grant70.4%
- Collaboration Revenue29.6%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 1 | 70.4% |
| Collaboration Revenue | $ 1 | 29.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Grant0%
- Gates Foundation Grant50.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 4 | - |
| Gates Foundation Grant | $ 1 | 50.4% |
Description of Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc (Arcturus) is a clinical stage biopharmaceutical company engaged in the discovery, development, and commercialization of RNA medicines. The company is headquartered in San Diego, California, and was founded in 201
Arcturus has developed a proprietary mRNA drug delivery platform called STARR (Self-Transcribing Active Replicating RNA). This platform allows for rapid and flexible development of RNA medicines that can target a variety of diseases. The main focus of the company is on developing RNA medicines for the treatment of rare diseases and vaccines for infectious diseases.
The company has a pipeline of RNA medicines at various stages of development. ARCT-021 is the lead product candidate, which is being developed in collaboration with Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). This candidate is being developed for the treatment of COVID-19 and is currently in Phase 2 clinical trials.
Arcturus is also developing ARCT-810, a potential treatment for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder. The company has received orphan drug designation for this candidate from the US FDA.
In addition to its own pipeline, Arcturus has formed partnerships with other pharmaceutical companies to develop RNA medicines for various indications. The company has partnerships with Ultragenyx Pharmaceutical and CureVac for the development of RNA medicines for rare diseases.
Arcturus has also entered into strategic alliances with various companies such as Thermo Fisher Scientific, Duke-NUS Medical School, and others to further advance its mRNA technology platform.
Arcturus has a strong management team with expertise in RNA technology, drug discovery, and development. The company has raised capital through various sources, including public offerings, private placements, and collaborations. As of 2021, the company has a market capitalization of approximately $4 billion.
Arcturus has developed a proprietary mRNA drug delivery platform called STARR (Self-Transcribing Active Replicating RNA). This platform allows for rapid and flexible development of RNA medicines that can target a variety of diseases. The main focus of the company is on developing RNA medicines for the treatment of rare diseases and vaccines for infectious diseases.
The company has a pipeline of RNA medicines at various stages of development. ARCT-021 is the lead product candidate, which is being developed in collaboration with Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). This candidate is being developed for the treatment of COVID-19 and is currently in Phase 2 clinical trials.
Arcturus is also developing ARCT-810, a potential treatment for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder. The company has received orphan drug designation for this candidate from the US FDA.
In addition to its own pipeline, Arcturus has formed partnerships with other pharmaceutical companies to develop RNA medicines for various indications. The company has partnerships with Ultragenyx Pharmaceutical and CureVac for the development of RNA medicines for rare diseases.
Arcturus has also entered into strategic alliances with various companies such as Thermo Fisher Scientific, Duke-NUS Medical School, and others to further advance its mRNA technology platform.
Arcturus has a strong management team with expertise in RNA technology, drug discovery, and development. The company has raised capital through various sources, including public offerings, private placements, and collaborations. As of 2021, the company has a market capitalization of approximately $4 billion.
Arcturus Therapeutics Holdings Inc. is a pioneering clinical-stage biotechnology organization that focuses on the innovative discovery, development, and commercialization of novel messenger RNA (mRNA) therapeutics. The company’s mission is to address unmet medical needs in various therapeutic areas, including rare genetic disorders, liver and respiratory diseases, and cancer through groundbreaking mRNA technology.
Segments
Arcturus Therapeutics operates within a singular business segment that pertains to the development and commercialization of mRNA therapeutics. Within this segment, the company has cultivated strategic alliances with several leading pharmaceutical and biotechnology firms, allowing for collaborative efforts to enhance their proprietary mRNA therapeutics platform and expedite the delivery of therapies to the market.
Products
Arcturus Therapeutics boasts a rich pipeline of promising mRNA-based products, some of which include:
1. ARCT-810: This investigational therapy targets ornithine transcarbamylase (OTC) deficiency, a rare metabolic disorder caused by a deficiency of the OTC enzyme, leading to the accumulation of ammonia in the bloodstream. By introducing a functional copy of the gene responsible for producing the enzyme through mRNA, ARCT-810 aims to restore normal metabolic function.
2. ARCT-032: Developed to treat cystic fibrosis, a complex genetic disorder primarily affecting the lungs and digestive system, ARCT-032 utilizes mRNA technology to correct the underlying genetic defect, potentially improving lung function and quality of life for patients.
3. ARCT-021: This mRNA-based therapy is designed for the treatment of transthyretin-mediated amyloidosis (ATTR), a condition characterized by the buildup of amyloid proteins in bodily tissues, leading to dysfunction in multiple organs. ARCT-021 aims to reduce amyloid deposition and improve patient outcomes through targeted mRNA delivery.
4. ARCT-053: Targeting various forms of cancer, including prostate cancer, melanoma, and non-small cell lung cancer, ARCT-053 focuses on leveraging mRNA technology to elicit robust immune responses against tumors. By encoding specific antigens, this therapy aims to trigger the bodys own immune system to recognize and attack cancer cells effectively.
Services
In addition to its product development, Arcturus Therapeutics offers a comprehensive suite of services in the realm of mRNA research and development, drug discovery, and clinical progression, including:
1. mRNA Therapeutics Platform: At the core of Arcturus Therapeutics operations is its proprietary mRNA therapeutics platform, which facilitates the efficient development of novel mRNA-based therapies. This platform encompasses advanced technologies that enhance the delivery, stability, and efficacy of mRNA products.
2. Drug Discovery: The company has a dedicated drug discovery team that engages in cutting-edge research to identify new therapeutic targets which can be addressed by mRNA therapies. This involves extensive validation processes to ensure the viability of novel compounds.
3. Preclinical and Clinical Development: Arcturus Therapeutics manages all stages of preclinical and clinical development for its mRNA therapeutics. This includes conducting rigorous clinical trials to assess safety and efficacy, as well as navigating the intricate regulatory submissions required for bringing therapies to the marketplace.
Conclusion
Arcturus Therapeutics Holdings Inc. stands at the forefront of mRNA technology, leveraging its innovative platform to develop therapies that target a wide range of diseases. Through its extensive pipeline and collaborative efforts, the company aims to make significant strides in the treatment of complex health conditions, demonstrating the transformative potential of mRNA-based therapeutics in modern medicine.
Segments
Arcturus Therapeutics operates within a singular business segment that pertains to the development and commercialization of mRNA therapeutics. Within this segment, the company has cultivated strategic alliances with several leading pharmaceutical and biotechnology firms, allowing for collaborative efforts to enhance their proprietary mRNA therapeutics platform and expedite the delivery of therapies to the market.
Products
Arcturus Therapeutics boasts a rich pipeline of promising mRNA-based products, some of which include:
1. ARCT-810: This investigational therapy targets ornithine transcarbamylase (OTC) deficiency, a rare metabolic disorder caused by a deficiency of the OTC enzyme, leading to the accumulation of ammonia in the bloodstream. By introducing a functional copy of the gene responsible for producing the enzyme through mRNA, ARCT-810 aims to restore normal metabolic function.
2. ARCT-032: Developed to treat cystic fibrosis, a complex genetic disorder primarily affecting the lungs and digestive system, ARCT-032 utilizes mRNA technology to correct the underlying genetic defect, potentially improving lung function and quality of life for patients.
3. ARCT-021: This mRNA-based therapy is designed for the treatment of transthyretin-mediated amyloidosis (ATTR), a condition characterized by the buildup of amyloid proteins in bodily tissues, leading to dysfunction in multiple organs. ARCT-021 aims to reduce amyloid deposition and improve patient outcomes through targeted mRNA delivery.
4. ARCT-053: Targeting various forms of cancer, including prostate cancer, melanoma, and non-small cell lung cancer, ARCT-053 focuses on leveraging mRNA technology to elicit robust immune responses against tumors. By encoding specific antigens, this therapy aims to trigger the bodys own immune system to recognize and attack cancer cells effectively.
Services
In addition to its product development, Arcturus Therapeutics offers a comprehensive suite of services in the realm of mRNA research and development, drug discovery, and clinical progression, including:
1. mRNA Therapeutics Platform: At the core of Arcturus Therapeutics operations is its proprietary mRNA therapeutics platform, which facilitates the efficient development of novel mRNA-based therapies. This platform encompasses advanced technologies that enhance the delivery, stability, and efficacy of mRNA products.
2. Drug Discovery: The company has a dedicated drug discovery team that engages in cutting-edge research to identify new therapeutic targets which can be addressed by mRNA therapies. This involves extensive validation processes to ensure the viability of novel compounds.
3. Preclinical and Clinical Development: Arcturus Therapeutics manages all stages of preclinical and clinical development for its mRNA therapeutics. This includes conducting rigorous clinical trials to assess safety and efficacy, as well as navigating the intricate regulatory submissions required for bringing therapies to the marketplace.
Conclusion
Arcturus Therapeutics Holdings Inc. stands at the forefront of mRNA technology, leveraging its innovative platform to develop therapies that target a wide range of diseases. Through its extensive pipeline and collaborative efforts, the company aims to make significant strides in the treatment of complex health conditions, demonstrating the transformative potential of mRNA-based therapeutics in modern medicine.